Fallo F, Patrassi G, Girolami A, Castellano M, Beschi M, Mantero F
Institute of Semeiotica Medica, University of Padua, Italy.
J Hypertens Suppl. 1988 Dec;6(4):S675-7. doi: 10.1097/00004872-198812040-00212.
The aim of this study was to assess the cardiovascular and hormonal responses to 1-desamino-8,D-arginine vasopressin (DDAVP) in hypertensive patients before and after non-selective beta-blockade. We infused DDAVP at 400 ng/kg body weight for 10 min in nine subjects with mild essential hypertension before and 14 days after administration of nadolol at 80 mg/day. Blood pressure and heart rate were recorded, and blood was drawn at 0, 30 and 60 min for measurement of plasma renin activity, aldosterone, cortisol, noradrenaline, adrenaline and dopamine. Before the administration of nadolol, DDAVP induced a significant decrease in blood pressure, and significant increases in the heart rate, plasma renin activity, cortisol and noradrenaline; there were no changes in adrenaline or dopamine. After the administration of nadolol, baseline noradrenaline was significantly increased, while cortisol, adrenaline and dopamine remained unchanged. A second infusion of DDAVP did not significantly alter blood pressure, [corrected] heart rate, noradrenaline, adrenaline or dopamine, but plasma renin activity, aldosterone and cortisol still showed a significant increase. The blunted hypotensive effect of DDAVP after the administration of nadolol may be aspecific, due to lower basal blood pressure levels, or may indicate a mechanism of action common to both drugs. A similar post-DDAVP increase before and after beta-blockade suggests that the drug has a direct effect on the renin-secretory apparatus. An indirect effect, mediated by changes in intrarenal haemodynamics or by other factors with renin-stimulating activity, e.g. tissue plasminogen activator, can also be hypothesized.
本研究旨在评估非选择性β受体阻滞剂治疗前后高血压患者对1-去氨基-8-D-精氨酸加压素(DDAVP)的心血管及激素反应。我们对9名轻度原发性高血压患者,在每日服用80mg纳多洛尔前及服药14天后,均以400ng/kg体重的剂量静脉输注DDAVP 10分钟。记录血压和心率,并在0、30和60分钟时采血,检测血浆肾素活性、醛固酮、皮质醇、去甲肾上腺素、肾上腺素和多巴胺。在服用纳多洛尔前,DDAVP可使血压显著降低,心率、血浆肾素活性、皮质醇和去甲肾上腺素显著升高;肾上腺素和多巴胺无变化。服用纳多洛尔后,基线去甲肾上腺素显著升高,而皮质醇、肾上腺素和多巴胺保持不变。再次输注DDAVP未显著改变血压、心率、去甲肾上腺素、肾上腺素或多巴胺,但血浆肾素活性、醛固酮和皮质醇仍显著升高。服用纳多洛尔后DDAVP降压作用减弱可能是非特异性的,原因是基础血压水平较低,也可能提示两种药物有共同的作用机制。β受体阻滞剂治疗前后DDAVP给药后出现类似的升高,提示该药物对肾素分泌装置有直接作用。也可推测存在一种间接作用,由肾内血流动力学变化或其他具有肾素刺激活性的因素介导,如组织纤溶酶原激活剂。